7520-75-4

Basic information

• Product Name: CINNAMONITRILEE
• Synonyms: α-Methoxymethyl-4,5-dimethoxy-2-methylcinnamonitrile
• CAS NO: 7520-75-4
• Molecular Formula: C₁₄H₁₇NO₃
• Molecular Weight: 0
• Mol File: 7520-75-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CINNAMONITRILEE(CAS DataBase Reference)
• NIST Chemistry Reference: CINNAMONITRILEE(7520-75-4)
• EPA Substance Registry System: CINNAMONITRILEE(7520-75-4)

Safety Data

• Hazardous Substances Data: 7520-75-4(Hazardous Substances Data)

Upstream product

• 7721-62-2 4,5-dimethoxy-2-methylbenzaldehyde 
• 124-41-4 sodium methylate 
• 107-13-1 acrylonitrile 
• 494-99-5 1,2-dimethoxy-4-methylbenzene 
• 22002-45-5 2-bromo-4-methylanisole 

Downstream Products

• 6981-18-6 ormetoprim 
• 63940-81-8 (Z)-2-(4,5-Dimethoxy-2-methyl-benzyl)-3-methoxy-acrylonitrile 
• 7520-76-5 2-Cyan-3-<4,5-Dimethoxy-2-methyl-phenyl>-propionaldehyd-dimethylacetal 
• 141292-65-1 (E)-2-(4,5-Dimethoxy-2-methyl-benzyl)-3-dimethylamino-acrylonitrile 

Relevant articles and documents

Ormetoprim synthesis method

The invention provides an ormetoprim synthesis method. The method includes steps: subjecting p-cresol and dimethyl carbonate to phenolic hydroxymethylation to obtain a compound I; subjecting the compound I and potassium bromide to bromination reaction under an acetic anhydride-nitric acid system to obtain a compound II; taking cuprous chloride as a catalyst, and subjecting the compound II and sodium methylate methanol solution to methoxylation reaction to obtain a compound III; subjecting the compound III and a VHA reagent to formylation reaction to obtain a compound IV; subjecting the compound IV to reaction with sodium methylate and acrylonitrile methanol solution to obtain a compound V; after the compound V is subjected to alkali isomerization to obtain a vinyl ether structure, subjecting to addition reaction with methyl alcohol and direct condensation and cyclization with guanidine to finally obtain a compound VI which is a final product namely ormetoprim. Defects in the prior art are overcome, and the provided ormetoprim synthesis method has advantages of technical simplicity, easiness in acquisition of starting materials, high yield and low production cost.

Diaminopyrimidines as P2X3 and P2X2/3 antagonists

Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.